Biomarkers for risk prediction of mortality

• Main Authors: LATINI ROBERTO, KARL JOHANN, KAISER EDELGARD, MASSON SERGE, ZAUGG CHRISTIAN, ROLNY VINZENT, WIENHUES-THELEN URSULA-HENRIKE, BLOCK DIRK, DIETERLE THOMAS
• Format: Patent
• Language: Chinese; English
• Published: 29.11.2019
• Subjects: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; PHYSICS; TESTING

The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/ or death. Themethod is based on the determination of at least one bio marker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention. 本发明涉及用于预测对象快速进展为慢性心力衰竭和/或由于慢性心力衰竭而入院治疗和/或死亡的风险的方法。本发明基于测定对象样品中选自以下的至少一种生物标志物：BNP型肽、IGFBP7 (IGF结合蛋白7)、心肌肌钙蛋白、可溶性ST2 (sST2)、FGF-23 (成纤维细胞生长因子23)和生长分化因子15 (GDF-15)。所述方法可以进一步包括评估(i) 异常壁内缩短分数或(ii) 左心室肥大的存在与否。本发明进一步考虑到了适于进行本发明的装置。